NO330237B1 - Fremgangsmate for deteksjon av Mycoplasma pneumoniae ved anvedelse av oligonukleotid, amplifiseringsprimerpar og kit - Google Patents
Fremgangsmate for deteksjon av Mycoplasma pneumoniae ved anvedelse av oligonukleotid, amplifiseringsprimerpar og kit Download PDFInfo
- Publication number
- NO330237B1 NO330237B1 NO20034555A NO20034555A NO330237B1 NO 330237 B1 NO330237 B1 NO 330237B1 NO 20034555 A NO20034555 A NO 20034555A NO 20034555 A NO20034555 A NO 20034555A NO 330237 B1 NO330237 B1 NO 330237B1
- Authority
- NO
- Norway
- Prior art keywords
- seq
- amplification
- target
- sequence
- nucleic acid
- Prior art date
Links
- 238000003199 nucleic acid amplification method Methods 0.000 title claims description 171
- 230000003321 amplification Effects 0.000 title claims description 169
- 108091034117 Oligonucleotide Proteins 0.000 title claims description 55
- 241000202934 Mycoplasma pneumoniae Species 0.000 title claims description 39
- 238000000034 method Methods 0.000 title claims description 35
- 230000027455 binding Effects 0.000 claims description 76
- 238000006243 chemical reaction Methods 0.000 claims description 73
- 150000007523 nucleic acids Chemical class 0.000 claims description 61
- 108020004707 nucleic acids Proteins 0.000 claims description 42
- 102000039446 nucleic acids Human genes 0.000 claims description 42
- 230000000295 complement effect Effects 0.000 claims description 37
- 238000003752 polymerase chain reaction Methods 0.000 claims description 37
- 108091008146 restriction endonucleases Proteins 0.000 claims description 34
- 238000009396 hybridization Methods 0.000 claims description 31
- 238000001514 detection method Methods 0.000 claims description 29
- 101710087110 ORF6 protein Proteins 0.000 claims description 17
- 101710095001 Uncharacterized protein in nifU 5'region Proteins 0.000 claims description 17
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 15
- 238000006073 displacement reaction Methods 0.000 claims description 13
- 241000588832 Bordetella pertussis Species 0.000 claims description 3
- 206010061041 Chlamydial infection Diseases 0.000 claims 1
- 241000589248 Legionella Species 0.000 claims 1
- 208000007764 Legionnaires' Disease Diseases 0.000 claims 1
- 201000000902 chlamydia Diseases 0.000 claims 1
- 208000012538 chlamydia trachomatis infectious disease Diseases 0.000 claims 1
- 239000013615 primer Substances 0.000 description 149
- 239000000523 sample Substances 0.000 description 45
- 239000000047 product Substances 0.000 description 42
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 20
- 101150007210 ORF6 gene Proteins 0.000 description 19
- 238000004458 analytical method Methods 0.000 description 18
- 239000000975 dye Substances 0.000 description 17
- 230000008859 change Effects 0.000 description 15
- 238000005520 cutting process Methods 0.000 description 15
- 241000894007 species Species 0.000 description 13
- 238000003776 cleavage reaction Methods 0.000 description 12
- 239000003550 marker Substances 0.000 description 12
- 239000002773 nucleotide Substances 0.000 description 12
- 230000007017 scission Effects 0.000 description 12
- 108020004414 DNA Proteins 0.000 description 11
- 125000003729 nucleotide group Chemical group 0.000 description 11
- 102000004190 Enzymes Human genes 0.000 description 9
- 108090000790 Enzymes Proteins 0.000 description 9
- 238000003556 assay Methods 0.000 description 9
- 230000000694 effects Effects 0.000 description 9
- 238000012408 PCR amplification Methods 0.000 description 8
- 239000002253 acid Substances 0.000 description 8
- 150000007513 acids Chemical class 0.000 description 8
- 108091093088 Amplicon Proteins 0.000 description 7
- 230000015572 biosynthetic process Effects 0.000 description 7
- 238000010791 quenching Methods 0.000 description 6
- 230000000171 quenching effect Effects 0.000 description 6
- 239000007790 solid phase Substances 0.000 description 6
- 238000011144 upstream manufacturing Methods 0.000 description 6
- 230000000241 respiratory effect Effects 0.000 description 5
- 238000003786 synthesis reaction Methods 0.000 description 5
- 235000011178 triphosphate Nutrition 0.000 description 5
- 239000001226 triphosphate Substances 0.000 description 5
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 4
- 108060002716 Exonuclease Proteins 0.000 description 4
- 230000007423 decrease Effects 0.000 description 4
- 102000013165 exonuclease Human genes 0.000 description 4
- 239000011159 matrix material Substances 0.000 description 4
- 238000006116 polymerization reaction Methods 0.000 description 4
- 230000035945 sensitivity Effects 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- AHCYMLUZIRLXAA-SHYZEUOFSA-N Deoxyuridine 5'-triphosphate Chemical compound O1[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)C[C@@H]1N1C(=O)NC(=O)C=C1 AHCYMLUZIRLXAA-SHYZEUOFSA-N 0.000 description 3
- 241000204031 Mycoplasma Species 0.000 description 3
- 239000011543 agarose gel Substances 0.000 description 3
- 238000000137 annealing Methods 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 230000002950 deficient Effects 0.000 description 3
- 230000001419 dependent effect Effects 0.000 description 3
- 239000003446 ligand Substances 0.000 description 3
- 244000005700 microbiome Species 0.000 description 3
- 239000002987 primer (paints) Substances 0.000 description 3
- 239000011541 reaction mixture Substances 0.000 description 3
- 238000000926 separation method Methods 0.000 description 3
- OLXZPDWKRNYJJZ-UHFFFAOYSA-N 5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-ol Chemical compound C1=NC=2C(N)=NC=NC=2N1C1CC(O)C(CO)O1 OLXZPDWKRNYJJZ-UHFFFAOYSA-N 0.000 description 2
- 241000606161 Chlamydia Species 0.000 description 2
- 102000053602 DNA Human genes 0.000 description 2
- 239000003155 DNA primer Substances 0.000 description 2
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 2
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 2
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 2
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 2
- 108010042407 Endonucleases Proteins 0.000 description 2
- 102000004533 Endonucleases Human genes 0.000 description 2
- 241000589242 Legionella pneumophila Species 0.000 description 2
- 108010090804 Streptavidin Proteins 0.000 description 2
- ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical compound O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 description 2
- DRTQHJPVMGBUCF-XVFCMESISA-N Uridine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-XVFCMESISA-N 0.000 description 2
- 239000000427 antigen Substances 0.000 description 2
- 102000036639 antigens Human genes 0.000 description 2
- 108091007433 antigens Proteins 0.000 description 2
- 229960002685 biotin Drugs 0.000 description 2
- 235000020958 biotin Nutrition 0.000 description 2
- 239000011616 biotin Substances 0.000 description 2
- 239000007795 chemical reaction product Substances 0.000 description 2
- 238000012864 cross contamination Methods 0.000 description 2
- 230000001351 cycling effect Effects 0.000 description 2
- NHVNXKFIZYSCEB-XLPZGREQSA-N dTTP Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)C1 NHVNXKFIZYSCEB-XLPZGREQSA-N 0.000 description 2
- 238000004925 denaturation Methods 0.000 description 2
- 230000036425 denaturation Effects 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 238000002372 labelling Methods 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 230000000750 progressive effect Effects 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 238000010223 real-time analysis Methods 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000010076 replication Effects 0.000 description 2
- 238000011895 specific detection Methods 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- RWQNBRDOKXIBIV-UHFFFAOYSA-N thymine Chemical compound CC1=CNC(=O)NC1=O RWQNBRDOKXIBIV-UHFFFAOYSA-N 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- 125000002264 triphosphate group Chemical class [H]OP(=O)(O[H])OP(=O)(O[H])OP(=O)(O[H])O* 0.000 description 2
- UNXRWKVEANCORM-UHFFFAOYSA-N triphosphoric acid Chemical compound OP(O)(=O)OP(O)(=O)OP(O)(O)=O UNXRWKVEANCORM-UHFFFAOYSA-N 0.000 description 2
- 208000035657 Abasia Diseases 0.000 description 1
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- 206010003757 Atypical pneumonia Diseases 0.000 description 1
- 108090001008 Avidin Proteins 0.000 description 1
- 102000052510 DNA-Binding Proteins Human genes 0.000 description 1
- 101710096438 DNA-binding protein Proteins 0.000 description 1
- 101150016555 ERF6 gene Proteins 0.000 description 1
- 101800001466 Envelope glycoprotein E1 Proteins 0.000 description 1
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 101100017567 Mycoplasma gallisepticum (strain R(low / passage 15 / clone 2)) hlp1 gene Proteins 0.000 description 1
- 101100395360 Mycoplasma gallisepticum (strain R(low / passage 15 / clone 2)) hlp3 gene Proteins 0.000 description 1
- 108700026244 Open Reading Frames Proteins 0.000 description 1
- 201000007100 Pharyngitis Diseases 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- 206010057190 Respiratory tract infections Diseases 0.000 description 1
- 238000012300 Sequence Analysis Methods 0.000 description 1
- 108020004682 Single-Stranded DNA Proteins 0.000 description 1
- 101800001690 Transmembrane protein gp41 Proteins 0.000 description 1
- 102000006943 Uracil-DNA Glycosidase Human genes 0.000 description 1
- 108010072685 Uracil-DNA Glycosidase Proteins 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 238000000246 agarose gel electrophoresis Methods 0.000 description 1
- 230000000692 anti-sense effect Effects 0.000 description 1
- 238000003491 array Methods 0.000 description 1
- 238000000376 autoradiography Methods 0.000 description 1
- 238000002869 basic local alignment search tool Methods 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- DRTQHJPVMGBUCF-PSQAKQOGSA-N beta-L-uridine Natural products O[C@H]1[C@@H](O)[C@H](CO)O[C@@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-PSQAKQOGSA-N 0.000 description 1
- 206010006451 bronchitis Diseases 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 239000005081 chemiluminescent agent Substances 0.000 description 1
- 238000004590 computer program Methods 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- SUYVUBYJARFZHO-RRKCRQDMSA-N dATP Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-RRKCRQDMSA-N 0.000 description 1
- SUYVUBYJARFZHO-UHFFFAOYSA-N dATP Natural products C1=NC=2C(N)=NC=NC=2N1C1CC(O)C(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-UHFFFAOYSA-N 0.000 description 1
- RGWHQCVHVJXOKC-SHYZEUOFSA-J dCTP(4-) Chemical compound O=C1N=C(N)C=CN1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)C1 RGWHQCVHVJXOKC-SHYZEUOFSA-J 0.000 description 1
- HAAZLUGHYHWQIW-KVQBGUIXSA-N dGTP Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 HAAZLUGHYHWQIW-KVQBGUIXSA-N 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 238000002405 diagnostic procedure Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- ZMMJGEGLRURXTF-UHFFFAOYSA-N ethidium bromide Chemical compound [Br-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 ZMMJGEGLRURXTF-UHFFFAOYSA-N 0.000 description 1
- 229960005542 ethidium bromide Drugs 0.000 description 1
- 101150051207 hmw3 gene Proteins 0.000 description 1
- 230000003100 immobilizing effect Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 238000011901 isothermal amplification Methods 0.000 description 1
- 238000011005 laboratory method Methods 0.000 description 1
- 229940115932 legionella pneumophila Drugs 0.000 description 1
- 238000013507 mapping Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- -1 nucleotide triphosphates Chemical class 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000007918 pathogenicity Effects 0.000 description 1
- 239000013610 patient sample Substances 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000037452 priming Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 230000003252 repetitive effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 238000002764 solid phase assay Methods 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- 108010068698 spleen exonuclease Proteins 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 229940113082 thymine Drugs 0.000 description 1
- 108091005703 transmembrane proteins Proteins 0.000 description 1
- 102000035160 transmembrane proteins Human genes 0.000 description 1
- 229940035893 uracil Drugs 0.000 description 1
- DRTQHJPVMGBUCF-UHFFFAOYSA-N uracil arabinoside Natural products OC1C(O)C(CO)OC1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-UHFFFAOYSA-N 0.000 description 1
- 229940045145 uridine Drugs 0.000 description 1
- 238000012070 whole genome sequencing analysis Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6888—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms
- C12Q1/6893—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms for protozoa
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6813—Hybridisation assays
- C12Q1/6827—Hybridisation assays for detection of mutation or polymorphism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6888—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms
- C12Q1/689—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms for bacteria
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Health & Medical Sciences (AREA)
- Analytical Chemistry (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Biotechnology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Tropical Medicine & Parasitology (AREA)
- Pathology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US28360101P | 2001-04-13 | 2001-04-13 | |
| PCT/US2002/011630 WO2002086441A2 (en) | 2001-04-13 | 2002-04-11 | Amplification and detection of mycoplasma pneumoniae |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| NO20034555D0 NO20034555D0 (no) | 2003-10-10 |
| NO20034555L NO20034555L (no) | 2003-12-09 |
| NO330237B1 true NO330237B1 (no) | 2011-03-14 |
Family
ID=23086794
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20034555A NO330237B1 (no) | 2001-04-13 | 2003-10-10 | Fremgangsmate for deteksjon av Mycoplasma pneumoniae ved anvedelse av oligonukleotid, amplifiseringsprimerpar og kit |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20040219544A1 (de) |
| EP (1) | EP1390710B1 (de) |
| JP (2) | JP4299003B2 (de) |
| AT (1) | ATE319731T1 (de) |
| AU (1) | AU2002303339B2 (de) |
| CA (1) | CA2443776A1 (de) |
| DE (1) | DE60209711T2 (de) |
| DK (1) | DK1390710T3 (de) |
| ES (1) | ES2257549T3 (de) |
| NO (1) | NO330237B1 (de) |
| WO (1) | WO2002086441A2 (de) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2267166B1 (de) * | 2003-04-25 | 2016-01-13 | Becton Dickinson and Company | Erkennung der Herpes-simplex-Viren Typ 1 und 2 mittels Nucleinsäureamplifikation |
| CN104946769B (zh) * | 2015-06-30 | 2017-11-07 | 中国疾病预防控制中心传染病预防控制所 | 肺炎支原体快速检测和基因分型的试剂盒 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP3092163B2 (ja) * | 1995-09-21 | 2000-09-25 | ベクトン ディキンソン アンド カンパニー | 好熱性鎖置換増幅による細胞中の核酸の検出 |
| US5817463A (en) * | 1996-06-28 | 1998-10-06 | Abbott Laboratories | Nucleic acid primers and probes for detecting Mycoplasma pneumoniae |
| FR2775002B1 (fr) * | 1998-02-19 | 2003-01-10 | France Etat | Procede de diagnostic d'agents pathogenes respiratoires par biologie moleculaire |
| US6277582B1 (en) * | 2000-07-27 | 2001-08-21 | Becton, Dickinson And Company | Amplification and detection of mycoplasma pneumoniae targeting the P1 gene |
-
2002
- 2002-04-11 WO PCT/US2002/011630 patent/WO2002086441A2/en active IP Right Grant
- 2002-04-11 JP JP2002583925A patent/JP4299003B2/ja not_active Expired - Fee Related
- 2002-04-11 AT AT02731359T patent/ATE319731T1/de not_active IP Right Cessation
- 2002-04-11 DE DE60209711T patent/DE60209711T2/de not_active Expired - Lifetime
- 2002-04-11 US US10/474,632 patent/US20040219544A1/en not_active Abandoned
- 2002-04-11 AU AU2002303339A patent/AU2002303339B2/en not_active Ceased
- 2002-04-11 DK DK02731359T patent/DK1390710T3/da active
- 2002-04-11 CA CA002443776A patent/CA2443776A1/en not_active Abandoned
- 2002-04-11 ES ES02731359T patent/ES2257549T3/es not_active Expired - Lifetime
- 2002-04-11 EP EP02731359A patent/EP1390710B1/de not_active Expired - Lifetime
-
2003
- 2003-10-10 NO NO20034555A patent/NO330237B1/no not_active IP Right Cessation
-
2008
- 2008-09-09 JP JP2008231464A patent/JP2009060901A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| WO2002086441A2 (en) | 2002-10-31 |
| US20040219544A1 (en) | 2004-11-04 |
| NO20034555D0 (no) | 2003-10-10 |
| ES2257549T3 (es) | 2006-08-01 |
| JP2005508136A (ja) | 2005-03-31 |
| JP4299003B2 (ja) | 2009-07-22 |
| DE60209711D1 (de) | 2006-05-04 |
| JP2009060901A (ja) | 2009-03-26 |
| EP1390710A4 (de) | 2005-07-13 |
| ATE319731T1 (de) | 2006-03-15 |
| AU2002303339B2 (en) | 2008-08-07 |
| NO20034555L (no) | 2003-12-09 |
| CA2443776A1 (en) | 2002-10-31 |
| DK1390710T3 (da) | 2006-07-17 |
| WO2002086441A3 (en) | 2003-04-17 |
| EP1390710B1 (de) | 2006-03-08 |
| EP1390710A2 (de) | 2004-02-25 |
| DE60209711T2 (de) | 2006-11-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11773457B2 (en) | Assay for Trichomonas vaginalis by amplification and detection of Trichomonas vaginalis AP65-1 gene | |
| EP1211324A2 (de) | Amplifizierung und Detektion von Organismen der Chlamydienfamilie | |
| JP4727771B2 (ja) | 増幅によるクラミジア・トラコマティスの分析およびクラミジア・トラコマティスの核酸の検出 | |
| EP1176213B1 (de) | Vervielfältigung und Detektion von Legionella pneumophila Nukleinsäuren | |
| US9777336B2 (en) | Assay for Chlamydia trachomatis by amplification and detection of Chlamydia trachomatis cytotoxin gene | |
| EP1176215B1 (de) | Amplifizierung und Detektion von Mycoplasma pneumoniae | |
| EP1176214A2 (de) | Verfahren zur Amplifizierung und Erkennung von Bordetella pertussis | |
| US6399309B1 (en) | Amplification and detection of mycoplasma pneumoniae targeting the ORF9 region of the hmw gene cluster | |
| US8492092B2 (en) | Assay for Chlamydia trachomatis by amplification and detection of Chlamydia trachomatis PMPA gene | |
| NO330237B1 (no) | Fremgangsmate for deteksjon av Mycoplasma pneumoniae ved anvedelse av oligonukleotid, amplifiseringsprimerpar og kit | |
| AU2002303339A1 (en) | Amplification and detection of Mycoplasma Pneumoniae |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM1K | Lapsed by not paying the annual fees |